LONDON: AstraZeneca‘s COVID-19 vaccine has been granted a conditional marketing authorisation (CMA) in the European Union (EU) for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 18 years of age and older. Following review of the application, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency based its…
All posts tagged AstraZeneca
AstraZeneca’s Imfinzi approved in the European Union and the UK
LONDON: AstraZeneca‘s Imfinzi (durvalumab) has been approved in the European Union and the UK for an additional dosing option, a 1,500mg fixed dose every four weeks, in locally advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 on at least 1% of tumour cells and whose disease has not progressed following…
AstraZeneca completes Atacand divestment to Cheplapharm in more than 70 countries
LONDON, UK: AstraZeneca has completed the divestment of commercial rights to Atacand (candesartan cilexetil) and Atacand Plus (a fixed-dose combination of candesartan cilexetil and hydrochlorothiazide) in over 70 countries to Cheplapharm Arzneimittel GmbH (Cheplapharm). Under the terms of the agreement AstraZeneca received a payment of $250m from Cheplapharm. AstraZeneca will receive further non-contingent payments equal…
AstraZeneca signs definitive agreement to acquire Alexion Pharmaceuticals
CAMBRIDGE: AstraZeneca and Alexion Pharmaceuticals Inc. have entered into a definitive agreement for AstraZeneca to acquire Alexion, a news release said. Alexion shareholders will receive $60 in cash and 2.1243 AstraZeneca American Depositary Shares (ADSs) (each ADS representing one-half of one (1/2) ordinary share of AstraZeneca, as evidenced by American Depositary Receipts (ADRs)) for each…
AstraZeneca sells Crestor to Grünenthal in Europe in a $320 million deal
LONDON: AstraZeneca has agreed to sell the rights to Crestor (rosuvastatin) and associated medicines in over 30 countries in Europe, except the UK and Spain, to Grünenthal GmbH (Grünenthal). Crestor is a statin approved for the treatment of dyslipidaemia and hypercholesterolaemia. Ruud Dobber, Executive Vice President, BioPharmaceuticals Business Unit, said: “This agreement supports the management…
Lonza signs agreement to manufacture AstraZeneca’s COVID-19 treatment
BASEL: Lonza has signed an agreement with AstraZeneca to manufacture AZD7442, a combination of two long-acting antibodies (LAABs) for the potential prevention and treatment of COVID-19, a news release said. AZD7442 is currently in Phase-I clinical studies and AstraZeneca plans to advance the LAAB combination into Phase-3 trials in the coming weeks. The agreement enables…
AstraZeneca agrees to sell commercial rights to Atacand to Cheplapharm Arzneimittel GmbH
LONDON: AstraZeneca has agreed to sell the commercial rights to Atacand (candesartan cilexetil) and Atacand Plus (a fixed-dose combination of candesartan cilexetil and hydrochlorothiazide) in around 70 countries globally to Cheplapharm Arzneimittel GmbH (Cheplapharm). Cheplapharm will pay AstraZeneca a total of $400m in non-contingent consideration, of which the present value will be recognised as Other…
AstraZeneca’s COVID-19 long-acting antibody combination advances into Phase III clinical trials
LONDON: AstraZeneca’s long-acting antibody (LAAB) combination, AZD7442, will advance into two Phase III clinical trials in more than 6,000 participants at sites in and outside the US that are due to begin in the next weeks, a news release said. AstraZeneca has received support of around $486 million from the US Government for the development…
AstraZeneca to list US ADR equity and all US debt securities on Nasdaq
LONDON: AstraZeneca today announced that it will be transferring the listing of its American Depositary Receipts (ADRs) and its US-listed debt securities from the New York Stock Exchange (NYSE) to the Nasdaq Global Select Market (Nasdaq) and Nasdaq Bond Exchange respectively. The transfers will be effective after market close on Thursday 24 September 2020. AstraZeneca…
RenalytixAI, AstraZeneca to develop and launch precision medicine strategies
NEW YORK: Renalytix AI plc announced a collaboration with AstraZeneca to develop and launch precision medicine strategies for cardiovascular, renal and metabolic diseases. The first stage in the collaboration will use KidneyIntelX, an artificial intelligence-enabled in vitro diagnostic platform, to examine further improving outcomes for patients with chronic kidney disease (CKD) and its complications, in…
AstraZeneca announces a three-tranche $3 billion global bond offering
LONDON: AstraZeneca PLC announces that, on 3 August 2020, it priced a three tranche global bond offering totalling $3bn. The offering is expected to close on 6 August 2020, subject to customary closing conditions. AstraZeneca expects to use the net proceeds of the issue for general corporate purposes, which may include the refinancing of existing…
AstraZeneca and Daiichi Sankyo enter collaboration to develop and commercialise oncology treatment
LONDON: AstraZeneca has entered into a new global development and commercialisation agreement with Daiichi Sankyo Company Limited for DS-1062, Daiichi Sankyo’s proprietary trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC) and potential new medicine for the treatment of multiple tumour types. DS-1062 is currently in development for the treatment of multiple tumours that commonly…